Edition:
United States

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.06USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,246
52-wk High
$2.44
52-wk Low
$0.48

Chart for

About

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary... (more)

Overall

Beta: --
Market Cap(Mil.): $73.15
Shares Outstanding(Mil.): 35.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

Nov 30 2017

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

Nov 07 2017

BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

* Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing

Oct 24 2017

BRIEF-Bellerophon announces $23 million private placement

* Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​

Sep 27 2017

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

Sep 05 2017

BRIEF-Bellerophon reports Q2 loss per share $0.12

* Bellerophon reports second quarter 2017 financial results and provides business update

Aug 07 2017

BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse

* Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Aug 03 2017

Earnings vs. Estimates